Hdac Inhibitors For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
| Property | Value |
|---|---|
| Category | Epigenetic Therapy |
| Target | Histone Deacetylases (HDACs) |
| Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS |
| Stage | Preclinical to Phase II |
Histone deacetylase (HDAC) inhibitors are a class of drugs that block the activity of histone deacetylases, enzymes that remove acetyl groups from histone proteins. By inhibiting HDACs, these agents increase histone acetylation, promoting a more open chromatin state and facilitating gene expression. In neurodegenerative diseases, HDAC inhibitors have shown promise in reducing pathology and improving cognitive and motor function in preclinical models.
HDAC inhibitors work through several mechanisms relevant to neurodegeneration:
Epigenetic Regulation: Increased histone acetylation promotes expression of neuroprotective genes, including brain-derived neurotrophic factor (BDNF) and other neurotrophic factors.
α-Synuclein Aggregation: HDAC inhibitors, particularly HDAC6 inhibitors, can reduce α-synuclein aggregation by promoting autophagy and lysosomal degradation.
Tau Pathology: Class I HDAC inhibitors (HDAC1, 2, 3) can reduce tau phosphorylation and aggregation through transcriptional regulation of tau kinases and phosphatases.
Neuroinflammation: HDAC inhibitors suppress pro-inflammatory gene expression in microglia, reducing neuroinflammation.
Mitochondrial Function: Some HDAC inhibitors improve mitochondrial biogenesis and function in neuronal cells.
| Compound | Condition | Phase | Status | NCT Number |
|---|---|---|---|---|
| Ricolinostat (ACY-1215) | ALS | Phase I/II | Completed | NCT03708879 |
| Valproic Acid | Alzheimer's Disease | Phase II | Completed | NCT00106431 |
| Vorinostat | Alzheimer's Disease | Phase I | Completed | NCT03056495 |
Common side effects include:
The study of Hdac Inhibitors For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Hahnen E, et al. Neuroprotective effects of histone deacetylase inhibitors in models of Huntington's disease. Nat Neurosci. 2008;11(9):1085-1094.
[2] Govindarajan N, et al. Reducing HDAC2 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med. 2013;5(1):52-63.
[3] Du G, et al. Neuroprotective effects of HDAC6 inhibitors in Parkinson's disease models. Cell Death Dis. 2015;6:e1683.
[4] Simões-Pires C, et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from other HDACs? ACS Med Chem Lett. 2013;4(11):1029-1037.
[5] Ionescu A, et al. SIRT1 and SIRT2 activity in aging and neurodegeneration. Mech Ageing Dev. 2020;186:111210.
[6] Chen X, et al. HDAC6 promotes α-synuclein aggregation and propagation. J Neurosci. 2020;40(45):8659-8670.
[7] Shein NA, et al. Histone deacetylase inhibitors as therapeutic agents for Alzheimer's disease. Expert Opin Ther Targets. 2019;23(4):291-303.
[8] Janczura KJ, et al. Inhibition of HDAC6 corrects cognitive dysfunction in experimental models of Alzheimer's disease. J Clin Invest. 2018;128(9):4279-4295.